270 related articles for article (PubMed ID: 29480206)
21. The Efficacy and Safety of Pridopidine on Treatment of Patients with Huntington's Disease: A Systematic Review and Meta-Analysis.
Asla MM; Nawar AA; Abdelsalam A; Elsayed E; Rizk MA; Hussein MA; Kamel WA
Mov Disord Clin Pract; 2022 Jan; 9(1):20-30. PubMed ID: 35005061
[TBL] [Abstract][Full Text] [Related]
22. Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Chen S; Liang T; Xue T; Xue S; Xue Q
Front Neurol; 2021; 12():658123. PubMed ID: 34054700
[No Abstract] [Full Text] [Related]
23. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [
Grachev ID; Meyer PM; Becker GA; Bronzel M; Marsteller D; Pastino G; Voges O; Rabinovich L; Knebel H; Zientek F; Rullmann M; Sattler B; Patt M; Gerhards T; Strauss M; Kluge A; Brust P; Savola JM; Gordon MF; Geva M; Hesse S; Barthel H; Hayden MR; Sabri O
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1103-1115. PubMed ID: 32995944
[TBL] [Abstract][Full Text] [Related]
24. The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.
Naia L; Ly P; Mota SI; Lopes C; Maranga C; Coelho P; Gershoni-Emek N; Ankarcrona M; Geva M; Hayden MR; Rego AC
Neurotherapeutics; 2021 Apr; 18(2):1017-1038. PubMed ID: 33797036
[TBL] [Abstract][Full Text] [Related]
25. Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose.
Darpo B; Geva M; Ferber G; Goldberg YP; Cruz-Herranz A; Mehra M; Kovacs R; Hayden MR
Neurol Ther; 2023 Apr; 12(2):597-617. PubMed ID: 36811812
[TBL] [Abstract][Full Text] [Related]
26. The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins.
Ruiz C; Casarejos MJ; Rubio I; Gines S; Puigdellivol M; Alberch J; Mena MA; de Yebenes JG
Brain Res; 2012 Jun; 1459():100-12. PubMed ID: 22560595
[TBL] [Abstract][Full Text] [Related]
27. Effects of the Dopamine Stabilizer, Pridopidine, on Basal and Phencyclidine-Induced Locomotion: Role of Dopamine D2 and Sigma-1 Receptors.
Sahlholm K; Valle-Leon M; Taura J; Fernandez-Duenas V; Ciruela F
CNS Neurol Disord Drug Targets; 2018; 17(7):522-527. PubMed ID: 29952269
[TBL] [Abstract][Full Text] [Related]
28. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
Choi ML; Begeti F; Oh JH; Lee SY; O'Keeffe GC; Clelland CD; Tyers P; Cho ZH; Kim YB; Barker RA
Neurobiol Dis; 2014 Jun; 66():19-27. PubMed ID: 24561069
[TBL] [Abstract][Full Text] [Related]
29. Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.
Esmaeilzadeh M; Kullingsjö J; Ullman H; Varrone A; Tedroff J
Clin Neuropharmacol; 2011; 34(3):95-100. PubMed ID: 21586914
[TBL] [Abstract][Full Text] [Related]
30. The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.
Rabinovich-Guilatt L; Siegler KE; Schultz A; Halabi A; Rembratt A; Spiegelstein O
Br J Clin Pharmacol; 2016 Feb; 81(2):246-55. PubMed ID: 26407011
[TBL] [Abstract][Full Text] [Related]
31. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
32. Pridopidine in treatment of Huntington's disease: beyond chorea?
Feigin A
Lancet Neurol; 2011 Dec; 10(12):1036-7. PubMed ID: 22071278
[No Abstract] [Full Text] [Related]
33. Changes in striatal activity and functional connectivity in a mouse model of Huntington's disease.
Cabanas M; Bassil F; Mons N; Garret M; Cho YH
PLoS One; 2017; 12(9):e0184580. PubMed ID: 28934250
[TBL] [Abstract][Full Text] [Related]
34. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
35. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
36. The improvement of motor symptoms in Huntington's disease during cariprazine treatment.
Csehi R; Molnar V; Fedor M; Zsumbera V; Palasti A; Acsai K; Grosz Z; Nemeth G; Molnar MJ
Orphanet J Rare Dis; 2023 Dec; 18(1):375. PubMed ID: 38041194
[TBL] [Abstract][Full Text] [Related]
37. Functional connectivity modeling of consistent cortico-striatal degeneration in Huntington's disease.
Dogan I; Eickhoff CR; Fox PT; Laird AR; Schulz JB; Eickhoff SB; Reetz K
Neuroimage Clin; 2015; 7():640-52. PubMed ID: 25844318
[TBL] [Abstract][Full Text] [Related]
38. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
[TBL] [Abstract][Full Text] [Related]
39. One-year safety and tolerability profile of pridopidine in patients with Huntington disease.
Squitieri F; Landwehrmeyer B; Reilmann R; Rosser A; de Yebenes JG; Prang A; Ivkovic J; Bright J; Rembratt A
Neurology; 2013 Mar; 80(12):1086-94. PubMed ID: 23446684
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Pettersson F; Pontén H; Waters N; Waters S; Sonesson C
J Med Chem; 2010 Mar; 53(6):2510-20. PubMed ID: 20155917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
